

Arjun Muralidharan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1480148/publications.pdf>

Version: 2024-02-01

17
papers

468
citations

687363

13
h-index

940533

16
g-index

18
all docs

18
docs citations

18
times ranked

770
citing authors

#	ARTICLE	IF	CITATIONS
1	A Small Molecule Angiotensin II Type 2 Receptor (AT ₂ R) Antagonist Produces Analgesia in a Rat Model of Neuropathic Pain by Inhibition of p38 Mitogen-Activated Protein Kinase (MAPK) and p44/p42 MAPK Activation in the Dorsal Root Ganglia. <i>Pain Medicine</i> , 2013, 14, 1557-1568.	1.9	66
2	A novel 5-HT _{2A} receptor antagonist exhibits antidepressant-like effects in a battery of rodent behavioural assays: Approaching early-onset antidepressants. <i>Pharmacology Biochemistry and Behavior</i> , 2010, 94, 363-373.	2.9	56
3	Analgesic Efficacy and Mode of Action of a Selective Small Molecule Angiotensin II Type 2 Receptor Antagonist in a Rat Model of Prostate Cancer-Induced Bone Pain. <i>Pain Medicine</i> , 2014, 15, 93-110.	1.9	45
4	Pain, analgesia and genetics. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 63, 1387-1400.	2.4	43
5	Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments. <i>Inflammopharmacology</i> , 2013, 21, 339-363.	3.9	38
6	Targeting angiotensin II type 2 receptor pathways to treat neuropathic pain and inflammatory pain. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 25-35.	3.4	32
7	Pharmacogenetics of pain and analgesia. <i>Clinical Genetics</i> , 2012, 82, 321-330.	2.0	31
8	Comparison of Burrowing and Stimuli-Evoked Pain Behaviors as End-Points in Rat Models of Inflammatory Pain and Peripheral Neuropathic Pain. <i>Frontiers in Behavioral Neuroscience</i> , 2016, 10, 88.	2.0	27
9	Optimization and characterization of a rat model of prostate cancer-induced bone pain using behavioral, pharmacological, radiological, histological and immunohistochemical methods. <i>Pharmacology Biochemistry and Behavior</i> , 2013, 106, 33-46.	2.9	26
10	Long-term male-specific chronic pain via telomere- and p53-mediated spinal cord cellular senescence. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	25
11	Discovery of molecules for the treatment of neuropathic pain: Synthesis, antiallodynic and antihyperalgesic activities of 5-(4-nitrophenyl)furoic-2-acid hydrazones. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 2964-2970.	5.5	20
12	The influence of aging and duration of nerve injury on the antiallodynic efficacy of analgesics in laboratory mice. <i>Pain Reports</i> , 2020, 5, e824.	2.7	17
13	Attenuation of the Infiltration of Angiotensin II Expressing CD3+ T-Cells and the Modulation of Nerve Growth Factor in Lumbar Dorsal Root Ganglia – A Possible Mechanism Underpinning Analgesia Produced by EMA300, An Angiotensin II Type 2 (AT ₂) Receptor Antagonist. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 389.	2.9	16
14	Establishment and Characterization of a Novel Rat Model of Mechanical Low Back Pain Using Behavioral, Pharmacologic and Histologic Methods. <i>Frontiers in Pharmacology</i> , 2017, 8, 493.	3.5	14
15	Peripheral α -straightjacket (α -Ca ^v ₂ channel subunit) expression is required for neuropathic sensitization in <i>Drosophila</i> . <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2019, 374, 20190287.	4.0	8
16	Identification and characterization of novel candidate compounds targeting μ - and δ -transmembrane μ -opioid receptor isoforms. <i>British Journal of Pharmacology</i> , 2021, 178, 2709-2726.	5.4	4
17	Comment on “protective arms of the renin-angiotensin system in neurological disease”. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2013, 40, 838-838.	1.9	0